SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

The community is focused on whether Robinhood will be added to the S&P 500, with many anticipating a decision after the bell and speculating on the potential price impact based on the outcome. Discussions also revolve around the implications of the S&P 500's quarterly rebalancing and potential inclusion, as well as how recent market volatility and economic data might influence the decision.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy (MSTR) is trending as investors eagerly await a decision on its potential inclusion in the S&P 500, with the announcement expected after hours. Community discussions revolve around whether MSTR or competitors like HOOD and APP will be selected, and the potential impact on the stock price and the broader crypto market. Some traders express concern over potential regulatory changes and the company's reliance on Bitcoin.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is trending amidst discussions of its potential S&P 500 inclusion and analyst upgrades, with community members debating its valuation and growth prospects. Bullish sentiment is fueled by strong earnings, AI-driven growth, and raised price targets, while some express concerns about insider selling and cyclical exposure. The stock's volatile price action is generating active trading and diverse opinions.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SOFI is trending as investors eagerly await potential inclusion in the S&P 500, with community chatter focused on the timing and likelihood of the announcement; some traders believe it's a done deal, while others express skepticism. The stock's intraday price swings and its relationship to broader market trends are also points of active discussion.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions about the Epstein files and Trump's potential involvement, with some users calling for their release while others defend him. Community members are also debating the stock's valuation and the broader implications of Trump's policies on the economy and international relations. The stock is highly divisive, with many users expressing strong opinions for and against Trump and his company.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending despite closing a $300 million investment from Uber, with the stock hitting new lows post reverse split. The community is actively discussing the company's financial health, potential for a short squeeze, and whether the reverse split was a strategic move or a sign of deeper issues. Some investors express long-term optimism while others voice concerns about management and the company's ability to compete in the EV market.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond ($BBBY) is trending amid discussions about its new corporate name and ticker symbol after Overstock acquired the rights, sparking confusion among investors. The community is buzzing about the potential of Tzero, a blockchain platform associated with the company, and its possible impact on preventing naked shorting, drawing comparisons to the $GME saga. Some traders are expressing skepticism while others speculate on Ryan Cohen's next move and the potential for new stores.

The Children's Place, Inc. engages in the provision of apparel, footwear, accessories, and other items for children. The firm also designs contracts to manufacture and sell fashionable and value-priced merchandise under the brand names of The Children’s Place, Baby Place, and Gymboree. It operates through The Children’s Place U.S. and The Children’s Place International segments. The Children’s Place U.S. segment refers to the company’s U.S. and Puerto Rico-based stores and revenue from its U.S. based wholesale business. The Children’s Place International segment is involved in the Canadian-based stores, revenue from the company’s Canadian-based wholesale business, as well as revenue from international franchisees. The company was founded by David Pulver and Clinton A. Clark in 1969 and is headquartered in Secaucus, NJ.

Childrens Place Inc

PLCE is trending due to speculation around a potential short squeeze, fueled by its high short interest and low float, with the community debating whether upcoming earnings will act as a catalyst. Investor discussion also centers on the impact of tariffs and Mithaq Capital's influence, with some drawing comparisons to other meme stocks. Meanwhile, some express concerns about the company's financial health and potential bankruptcy.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue ($KVUE) is trending as the FDA considers the ineffectiveness of phenylephrine, an ingredient in popular decongestants like Sudafed PE, potentially impacting sales. Despite this, some analysts remain bullish, citing attractive entry points and a recent addition to the S&P 500, with the community actively monitoring price movements for potential buying opportunities.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana's stock is trending as the community discusses its failure to be included in the S&P 500, with many calling the company a "scam." Traders are actively debating the implications for option values and potential market manipulation, particularly around the high cost of call options. Some investors are drawing comparisons to other companies, while others are pointing to insider selling as a reason to be cautious.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regencell Bioscience Holdings Ltd (3,500% Jump in Message Volume)Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism. Reports suggest its recent rally was fueled by insider buying, with insiders owning 81% of the company.&nbsp;However, a Stocktwits&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">poll</a> indicates retail traders remain skeptical, with some flagging it as a potential pump-and-dump risk.&nbsp;The stock has surged 1,054% this year.GlucoTrack Inc. (2,800% Jump in Message Volume)GlucoTrack develops non-invasive glucose monitoring devices. It announced that safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 ATTD conference.&nbsp;CEO Paul V. Goode highlighted its potential for real-time glucose monitoring without on-body wearables, calling it a transformative step in diabetes management.&nbsp;GlucoTrack stock is down over 96% year-to-date (YTD).TC Biopharm (Holdings) Plc (1,300% Jump in Message Volume)TC Biopharm&nbsp;<a href="https://stocktwits.com/symbol/TCBP">received</a> a Nasdaq delisting notice due to its share price falling below $1. Trading will be suspended on Monday, with its American depository shares expected to move to OTC Markets.&nbsp;The company is also shifting to a contract development and manufacturing organization (CDMO) model, cutting about 50% of its workforce to reduce operational burn by 55%. This is projected to save $2.1 million in 2025 and $4.2 million annually.&nbsp;The stock is down over 95% YTD.AbbVie Inc. (700% Jump in Message Volume)Erste Group upgraded AbbVie to ‘Buy’ from ‘Hold’, according to The Fly, citing strong sales growth projections through 2029, supported by upcoming product launches. The research firm expects earnings per share (EPS) to rise significantly in 2025, ranging from $12.12 to $12.32.&nbsp;AbbVie recently agreed to acquire a next-gen obesity drug from Denmark-based Gubra A/S for up to $2.2 billion, boosting sentiment.&nbsp;The stock is up over 17.5% YTD.Actinium Pharmaceuticals Inc. (600% Jump in Message Volume)Actinium is launching trials for its drug Actimab-A in combination with Merck’s Keytruda and Bristol Myers Squibb’s Opdivo to treat solid tumors. The trials will include head-to-head studies comparing Actimab-A combinations to standalone treatments.&nbsp;The company also entered a research agreement with Memorial Sloan Kettering to expand Actimab-A’s applications.&nbsp;Actinium stock is up over 22% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

Equity

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.


Nasdaq-listed shares of UK-based TC BioPharm (Holdings) PLC (TCBP) tumbled 64% by Friday afternoon after the biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tcbp-announces-transition-from-nasdaq-to-otc-markets-302408102.html">said</a> its securities would be delisted from the exchange.The delisting follows the company’s failure to maintain a minimum bid price of $1 per share. The company said that its management is working on an appeal with Nasdaq and expressed optimism that its American Depositary Shares will be eligible to trade on the OTC markets starting Monday.Earlier this week, the company announced a reduction in its workforce and other measures aimed at reducing core operational burn by 55% compared to last year. The layoff impacted approximately 20 employees, or <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tcbiopharm.com/news/press-releases/detail/122/tcbp-announces-outsourcing-initiatives-reducing-burn-rate">half of the company’s total headcount</a>.On Stocktwits, investors expressed frustration over the news.&nbsp;<stembedurl>https://stocktwits.com/Blackdog111/message/608838652</stembedurl>One user opined that there is little chance for recovery for the company’s stock.<stembedurl>https://stocktwits.com/Oxinternet/message/608832026</stembedurl>In early March, TC BioPharm announced that it had executed a non-binding letter of intent to acquire 100% of a commercial-stage ophthalmic pharmaceutical company in an all-stock transaction.CEO Bryan Kobel said the firm expects to execute the binding letter of intent in a few weeks and close the acquisition around the third quarter of this year.At the beginning of 2025, Kobel <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tcbp-issues-25-stock-dividend-302340235.html">said</a> he anticipated 2025 to be a “period of growth and development” for the company. He expressed “strong confidence” in the company’s financial future after issuing a special dividend of 0.25 &nbsp;American Depositary Shares (ADSs) for every ADS held by shareholders.&nbsp;The stock has dropped by over 94% this year, wiping nearly all its value over the past twelve months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rio-tinto-eyes-bigger-us-footprint-amid-copper-price-surge-fueled-by-trump-tariffs/ch7oTeGRb53">Rio Tinto Reportedly Eyes Bigger US Footprint Amid Copper Price Surge Fueled By Trump Tariffs – Stock Drops, Retail Sentiment Weakens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

TC BioPharm Stock Crashes On Nasdaq Delisting: Retail Expresses Frustration

The company said that its management is working on an appeal with Nasdaq and expressed optimism that its American Depositary Shares will be eligible to trade on the OTC markets starting Monday.

TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum

TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life...

TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial

TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial PR Newswire EDINBURGH, Scotland, Feb. 13...

TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial

TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical...

TCBP to Implement ADS Ratio Change

TCBP to Implement ADS Ratio Change TCBP to Implement ADS Ratio Change PR Newswire EDINBURGH, Scotland, Feb. 5, 2025 EDINBURGH, Scotland, Feb. 5, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ('TC...

TCBP Announces H5N1 Proof of Concept Studies Intention

TCBP Announces H5N1 Proof of Concept Studies Intention TCBP Announces H5N1 Proof of Concept Studies Intention PR Newswire EDINBURGH, Scotland, Jan. 15, 2025 EDINBURGH, Scotland, Jan. 15, 2025...

TCBP to Present at Sequire Investor Summit 2025

TCBP to Present at Sequire Investor Summit 2025 TCBP to Present at Sequire Investor Summit 2025 PR Newswire EDINBURGH, Scotland, Jan. 13, 2025 EDINBURGH, Scotland, Jan. 13, 2025 /PRNewswire/ -- TC...

TCBP Trading Continues Unabated on Nasdaq Stock Exchange

TCBP Trading Continues Unabated on Nasdaq Stock Exchange TCBP Trading Continues Unabated on Nasdaq Stock Exchange PR Newswire EDINBURGH, Scotland, Jan. 6, 2025 EDINBURGH, Scotland, Jan. 6, 2025...

TCBP Provides Update on Acquisition Strategy and Current Targets

TCBP Provides Update on Acquisition Strategy and Current Targets TCBP Provides Update on Acquisition Strategy and Current Targets PR Newswire EDINBURGH, Scotland, Dec. 31, 2024 EDINBURGH, Scotland...

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company was founded by Michael Leek and Angela Scott in 2013 and is headquartered in Motherwell, the United Kingdom.

Current Price	$0.202
Prev Close	$0.253
Open	$0.253
Dividend Yield	0.00%
50-Day Moving Average	$0.3035
Beta	0.69
Avg. Volume	6,635.24
PE Ratio	0.00

52-Week High	$131.95
52-Week Low	$0.08
Market Capitalization	$161,300.00
EPS (Annual)	-$164.58
Price to Book	0.13
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

TCBP
TC BioPharm Holdings Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest TCBP News

TCBP TC BioPharm Holdings Ltd